Literature DB >> 19352125

Elevated serum phosphate predicts mortality in renal transplant recipients.

Grainne M Connolly1, Ronan Cunningham, Peter T McNamee, Ian S Young, Alexander P Maxwell.   

Abstract

BACKGROUND: High serum phosphate has been identified as an important contributor to the vascular calcification seen in patients with chronic kidney disease (Block et al., Am J Kidney Dis 1998; 31: 607). In patients on hemodialysis, elevated serum phosphate levels are an independent predictor of mortality (Block et al., Am J Kidney Dis 1998; 31: 607; Block, Curr Opin Nephrol Hypertens 2001; 10: 741). The aim of this study was to investigate whether an elevated serum phosphate level was an independent predictor of mortality in patients with a renal transplant.
METHODS: Three hundred seventy-nine asymptomatic renal transplant recipients were recruited between June 2000 and December 2002. Serum phosphate was measured at baseline and prospective follow-up data were collected at a median of 2441 days after enrolment.
RESULTS: Serum phosphate was significantly higher in those renal transplant recipients who died at follow-up when compared with those who were still alive at follow-up (P<0.001). In Kaplan-Meier analysis, serum phosphate concentration was a significant predictor of mortality (P=0.0001). In multivariate Cox regression analysis, serum phosphate concentration remained a statistically significant predictor of all-cause mortality after adjustment for traditional cardiovascular risk factors, estimated glomerular filtration rate, and high sensitivity C reactive protein (P=0.036) and after adjustment for renal graft failure (P=0.001).
CONCLUSIONS: The results of this prospective study are the first to show that a higher serum phosphate is a predictor of mortality in patients with a renal transplant and suggest that serum phosphate provides additional, independent, prognostic information to that provided by traditional risk factors in the risk assessment of patients with a renal transplant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19352125     DOI: 10.1097/TP.0b013e31819cd122

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  27 in total

1.  Association of pretransplant serum phosphorus with posttransplant outcomes.

Authors:  Marcelo S Sampaio; Miklos Z Molnar; Csaba P Kovesdy; Rajnish Mehrotra; Istvan Mucsi; John J Sim; Mahesh Krishnan; Allen R Nissenson; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-29       Impact factor: 8.237

Review 2.  Management of mineral and bone disorder after kidney transplantation.

Authors:  Kamyar Kalantar-Zadeh; Miklos Z Molnar; Csaba P Kovesdy; Istvan Mucsi; Suphamai Bunnapradist
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

Review 3.  Mineral and bone disorder after kidney transplantation.

Authors:  Pahnwat T Taweesedt; Sinee Disthabanchong
Journal:  World J Transplant       Date:  2015-12-24

4.  Renal phosphate loss in long-term kidney transplantation.

Authors:  Supinda Sirilak; Kamonwan Chatsrisak; Atiporn Ingsathit; Surasak Kantachuvesiri; Vasant Sumethkul; Wasana Stitchantrakul; Piyanuch Radinahamed; Sinee Disthabanchong
Journal:  Clin J Am Soc Nephrol       Date:  2011-12-01       Impact factor: 8.237

Review 5.  A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

Authors:  Wendy L St. Peter; Lori D Wazny; Eric Weinhandl; Katie E Cardone; Joanna Q Hudson
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

6.  Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort.

Authors:  Basma Merhi; Theresa Shireman; Myra A Carpenter; John W Kusek; Paul Jacques; Marc Pfeffer; Madhumathi Rao; Meredith C Foster; S Joseph Kim; Todd E Pesavento; Stephen R Smith; Clifton E Kew; Andrew A House; Reginald Gohh; Daniel E Weiner; Andrew S Levey; Joachim H Ix; Andrew Bostom
Journal:  Am J Kidney Dis       Date:  2017-06-02       Impact factor: 8.860

7.  Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.

Authors:  Myles Wolf; Miklos Z Molnar; Ansel P Amaral; Maria E Czira; Anna Rudas; Akos Ujszaszi; Istvan Kiss; Laszlo Rosivall; Janos Kosa; Peter Lakatos; Csaba P Kovesdy; Istvan Mucsi
Journal:  J Am Soc Nephrol       Date:  2011-03-24       Impact factor: 10.121

8.  Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients.

Authors:  Zhong Ye; Juan P Palazzo; Liz Lin; Yinzhi Lai; Fran Guiles; Ronald E Myers; Jin Han; Jinliang Xing; Hushan Yang
Journal:  J Gastroenterol Hepatol       Date:  2013-09       Impact factor: 4.029

9.  Calcium, phosphate and parathyroid metabolism in kidney transplanted patients.

Authors:  Csaba Ambrus; Miklos Zsolt Molnar; Maria Eszter Czira; Laszlo Rosivall; Istvan Kiss; Adam Remport; Miklos Szathmari; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-08-22       Impact factor: 2.370

Review 10.  Phosphate and FGF-23 homeostasis after kidney transplantation.

Authors:  Leandro C Baia; Ita Pfeferman Heilberg; Gerjan Navis; Martin H de Borst
Journal:  Nat Rev Nephrol       Date:  2015-09-29       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.